The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

The closing of the Astellas collaboration for VIR-5500 validates the PROXTEN dual-masking platform, which is designed to widen the therapeutic index by limiting systemic toxicity while maintaining potent anti-tumor activity.

Management attributes the favorable safety profile of VIR-5500, specifically the absence of high-grade cytokine release syndrome (CRS), to the dual-masking technology that enables higher dosing without mandatory steroid premedication.

The strategic rationale for partnering with Astellas centers on their established global leadership in prostate cancer and a decade-long track record of co-developing category-defining therapies like Xtandi.

In hepatitis delta (HDV), management is positioning the tobevibart and elebsiran combination as a best-in-class regimen based on its ability to achieve 'target not detected' (TND) viral clearance, which they view as the gold standard for long-term clinical outcomes.

The HDV program's competitive advantage is driven by a once-monthly subcutaneous dosing schedule, contrasting with the daily or weekly requirements of current and emerging competitors.

Operational focus has shifted toward registrational-enabling studies, supported by a significantly strengthened balance sheet following recent collaborations and equity financing.

The company anticipates initiating a registrational Phase 3 program for VIR-5500 in 2027, with expansion cohorts in early-line and metastatic hormone-sensitive prostate cancer expected to begin in the coming months.

Preliminary response data for VIR-5818 (HER2-targeted) and VIR-5525 (EGFR-targeted) are expected in 2026 to inform dose selection and identify specific high-need tumor populations for further study.

Topline data from the ECLIPSE 1 trial in hepatitis delta is projected for the fourth quarter of 2026, followed by ECLIPSE 2 data in the first quarter of 2027 to support a potential BLA filing.

Management expects the U.S. launch of a competitor's therapy (bulevirtide) to benefit the market by increasing disease awareness, screening rates, and establishing treatment pathways for next-generation therapies.

The current cash runway is expected to extend into 2028, providing sufficient capital to reach multiple value-creating milestones across the oncology and infectious disease pipelines.

The Astellas agreement includes a $240 million upfront payment and a $75 million equity investment, with Vir eligible for up to $1.37 billion in future milestones plus tiered royalties.

A portion of certain collaboration proceeds from the Astellas deal will be shared with Sanofi under the terms of a prior licensing agreement.

R&D expenses decreased year-over-year primarily due to a non-recurring $30 million payment to Alnylam in 2025, though this was partially offset by HDV manufacturing and clinical costs.

The company completed a follow-on equity offering in February 2026, generating approximately $172.5 million in gross proceeds to fund its share of development costs.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management emphasized that their PROXTEN masking technology uses a consistent steric hindrance approach across programs, allowing them to translate safety learnings from one asset to another.

They believe their platform allows for significantly higher dosing than competitors, which is critical for achieving a viable therapeutic index in solid tumors.

Management noted that HDV is a severe orphan disease with European price benchmarks ranging from $60,000 to $165,000, while analyst estimates for the U.S. range from $150,000 to $250,000.

They highlighted that while only 10-15% of patients are currently diagnosed, the introduction of approved therapies and reflex testing could significantly expand the treated population.

Management argued that achieving 'target not detected' (TND) status is the most critical metric for preventing liver progression, where their combination showed 88% efficacy at 96 weeks.

They characterized competitor data showing only 5% TND for monthly dosing as potentially non-viable for long-term clinical success.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.